BioCentury
ARTICLE | Clinical News

Spectracef cefditoren pivoxil: Phase III data; NDA under review

September 25, 2000 7:00 AM UTC

In a Phase III equivalence trial, TAP said the clinical cure rates for evaluable patients receiving 200 and 400 mg of Spectracef were 81 and 78 percent, respectively, compared to 83 percent for patien...